HQ1 Stock Overview
A biotechnology company, develops novel biologics for the treatment of chronic skin diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oruka Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.70 |
| 52 Week High | US$27.80 |
| 52 Week Low | US$17.30 |
| Beta | 0 |
| 11 Month Change | -31.40% |
| 3 Month Change | -20.27% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| HQ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -14.9% | 0.8% | 0.8% |
| 1Y | n/a | -18.3% | 8.6% |
Return vs Industry: Insufficient data to determine how HQ1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how HQ1 performed against the German Market.
Price Volatility
| HQ1 volatility | |
|---|---|
| HQ1 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HQ1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine HQ1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Lawrence Klein | orukatx.com |
Oruka Therapeutics, Inc., a biotechnology company, develops novel biologics for the treatment of chronic skin diseases. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23 (IL-23p19); and ORKA-002 that targets interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of psoriasis psoriatic arthritis, and other inflammatory diseases. The company is based in Waltham, Massachusetts.
Oruka Therapeutics, Inc. Fundamentals Summary
| HQ1 fundamental statistics | |
|---|---|
| Market cap | €619.13m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs HQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HQ1 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did HQ1 perform over the long term?
See historical performance and comparison